BS_E4F1D721
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- os_event
- false
- age_years
- 26.321
- sex
- F
- race
- White
- e1_e2
- E2
- umap1_2d
- -8.465661529
- umap2_2d
- 0.229038148
- umap1_3d
- 0.202475856
- umap2_3d
- 2.549402288
- umap3_3d
- 2.276154472
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.540
- ANGIOGENESIS+0.460
- COAGULATION+0.430
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.370
- IL2_STAT5_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- ALLOGRAFT_REJECTION+0.320
- MYOGENESIS+0.290
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.460
- MITOTIC_SPINDLE-0.350
- DNA_REPAIR-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.240
- UV_RESPONSE_UP-0.190
- MTORC1_SIGNALING-0.150
- PEROXISOME-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_E4F1D721 | Spinal Cord Ependymoma | — | 0.939 |
| 2 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.926 |
| 3 | MDT-AP-0484 | Med | Medulloblastoma | 0.915 |
| 4 | TCGA-BH-A0DE-01A-11R-A115-07 | — | A | 0.913 |
| 5 | SRR1797296 | — | cohortMD2 | 0.911 |
| 6 | TCGA-55-7281-01A-11R-2039-07 | — | cohortA1 | 0.909 |
| 7 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.905 |
| 8 | SRR1797302 | — | cohortMD2 | 0.904 |
| 9 | TCGA-55-8091-01A-11R-2241-07 | — | cohortA1 | 0.903 |
| 10 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |